Boston, United States
CRISPR Therapeutics, a leader in biopharma and biotechnology, stands at the forefront of creating gene-based medicines for patients with serious diseases. Since its founding in 2013, the company has not only evolved but thrived by leveraging CRISPR technology, a Nobel Prize-winning innovation that has reshaped biomedical research.
The company's diverse portfolio includes groundbreaking therapies targeting hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. Notably, CRISPR Therapeutics made history with its CRISPR/Cas9 gene-edited therapy for sickle cell disease and beta thalassemia, receiving broad approval for CASGEVY® (exagamglogene autotemcel [exa-cel]) in late 2023.
Headquartered in the United States, the company maintains strong R&D operations in Boston and San Francisco. Strategic partnerships, including those with Vertex Pharmaceuticals, have bolstered its efforts. CRISPR Therapeutics recently secured a $585.20M post-IPO convertible investment, positioning itself for further growth and innovation.
